The mitogen-activated protein kinase pathway for molecular-targeted cancer treatment.
作者： Judith S. Sebolt-Leopold , Roman Herrera , Jeffrey F. Ohren
DOI: 10.1007/978-3-540-31209-3_9
关键词:
摘要: The molecular characterization of key events associated with tumor initiation and progression has led to the identification cellular signaling pathways that contribute not only normal cell functioning but also overall phenotype cancer. One such example is Ras-regulated kinase pathway. This module, comprising Raf, mitogen-activated protein (MEK), extracellular signal-regulated (ERK), plays a central role in regulating broad range events. In response diverse group stimuli including growth factors, cytokines, protooncogenes, activation this pathway results alterations proliferation, differentiation, survival. It therefore surprising been found be upregulated large percentage human tumors. While contributing uncontrolled enhanced survival cells, Ras-MAP their metastatic spread by motility invasion.
springer.com
sci-hub.st 参考文章(61)
Akiko Shimamura, Bryan A. Ballif, Stephanie A. Richards, John Blenis, Rsk1 mediates a MEK–MAP kinase cell survival signal Current Biology. ,vol. 10, pp. 127- 135 ,(2000) , 10.1016/S0960-9822(00)00310-9
David B. Solit, Levi A. Garraway, Christine A. Pratilas, Ayana Sawai, Gad Getz, Andrea Basso, Qing Ye, Jose M. Lobo, Yuhong She, Iman Osman, Todd R. Golub, Judith Sebolt-Leopold, William R. Sellers, Neal Rosen, BRAF mutation predicts sensitivity to MEK inhibition Nature. ,vol. 439, pp. 358- 362 ,(2006) , 10.1038/NATURE04304
Julian Downward, Targeting RAS signalling pathways in cancer therapy Nature Reviews Cancer. ,vol. 3, pp. 11- 22 ,(2003) , 10.1038/NRC969
Jeffrey A Frost, Helge Steen, Paul Shapiro, Tim Lewis, Natalie Ahn, Peter E Shaw, Melanie H Cobb, Cross-cascade activation of ERKs and ternary complex factors by Rho family proteins The EMBO Journal. ,vol. 16, pp. 6426- 6438 ,(1997) , 10.1093/EMBOJ/16.21.6426
Margaret F Favata, Kurumi Y Horiuchi, Elizabeth J Manos, Andrea J Daulerio, Deborah A Stradley, Wendi S Feeser, Drew E Van Dyk, William J Pitts, Richard A Earl, Frank Hobbs, Robert A Copeland, Ronald L Magolda, Peggy A Scherle, James M Trzaskos, None, IDENTIFICATION OF A NOVEL INHIBITOR OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE Journal of Biological Chemistry. ,vol. 273, pp. 18623- 18632 ,(1998) , 10.1074/JBC.273.29.18623
Makoto Fukuda, Yukiko Gotoh, Eisuke Nishida, Interaction of MAP kinase with MAP kinase kinase: its possible role in the control of nucleocytoplasmic transport of MAP kinase The EMBO Journal. ,vol. 16, pp. 1901- 1908 ,(1997) , 10.1093/EMBOJ/16.8.1901
J G Shelton, P W Moye, L S Steelman, W L Blalock, J T Lee, R A Franklin, M McMahon, J A McCubrey, Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation Leukemia. ,vol. 17, pp. 1765- 1782 ,(2003) , 10.1038/SJ.LEU.2403052
Walter Kolch, Coordinating ERK/MAPK signalling through scaffolds and inhibitors Nature Reviews Molecular Cell Biology. ,vol. 6, pp. 827- 837 ,(2005) , 10.1038/NRM1743
Kapaettu Satyamoorthy, Meenhard Herlyn, Patricia van Belle, Barbara L. Weber, David E. Elder, Patricia Volpe, Marcia S. Brose, Gang Li, Michelle R. Gerrero, Constitutive Mitogen-activated Protein Kinase Activation in Melanoma Is Mediated by Both BRAF Mutations and Autocrine Growth Factor Stimulation Cancer Research. ,vol. 63, pp. 756- 759 ,(2003)
Alison Maloney, Paul Workman, HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opinion on Biological Therapy. ,vol. 2, pp. 3- 24 ,(2002) , 10.1517/14712598.2.1.3